Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials

JAMA

Volumn 282, Issue 4, 1999, Pages 331-340

  Corey, Lawrence ^a,d,e   Langenberg, Andria G M ^a   Ashley, Rhoda ^f,g   Sekulovich, Rose E ^a   Izu, Allen E ^a   Douglas, John M ^a   Hunter Handsfield, H ^c   Warren, Terri ^a   Marr, Lisa ^a   Tyring, Stephen ^c   DiCarlo, Richard ^a   Adimora, Adaora A ^a   Leone, Peter ^c   Dekker, Cornelia L ^a   Burke, Rae Lyn ^b   Leong, Wai Ping ^a   Straus, Stephen E ^h,i  

^a Antigenics ^*

^b Antigenics Inc   (United States)

^c 3M COMPANY   (United States)

^d Wyeth Lederle Vaccines   (United States)

^e Diagnology   (Ireland)

^f MRL Diagnostics   (United States)

^g Viridae Clinical Sciences   (Canada)

^h ABBOTT LABORATORIES   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HERPES VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROPREVALENCE; VACCINATION; VIRUS CULTURE;

EID: 0033612702     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.4.331     Document Type: Article

References (45)

1. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337:1105-1111.
2. Koutsky LA, Ashley RL, Holmes KK, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex Transm Dis. 1990;17:90-94.
3. Cunningham AL, Lee FK, Ho DW, et al. Herpes simplex virus type 2 antibody in patients attending antenatal or STD clinics. Med J Aust. 1993;158:525-528.
4. Nahmias AJ, Lee FK, Beckman-Nahmias S. Seroepidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl. 1990;69:19-36.
5. Siegel D, Golden E, Washington AE, et al. Prevalence and correlates of herpes simplex infections: the population-based AIDS in Multiethnic Neighborhoods Study. JAMA. 1992;268:1702-1708.
6. Forsgren M. Genital herpes simplex virus infection and incidence of neonatal disease in Sweden. Scand J Infect Dis Suppl. 1990;69:37-41.
7. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509-515.
8. Holmberg SD, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA. 1988;259:1048-1050.
9. Wasserheit JN. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19:61-77.
10. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. 1998;280:61-66.
11. Brown ZA, Vontver LA, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med. 1987;317:1246-1251.
12. Yeager AS, Arvin AM, Urbani LJ, Kemp JA III. Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun. 1980;29:532-538.
13. Sullender WM, Miller JL, Yasukawa LL, et al. Humoral and cell-mediated immunity in neonates with herpes simplex virus infection. J Infect Dis. 1987;155: 28-37.
14. Schmidt OW, Fife KH, Corey L. Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis. 1984;149:645-646.
15. Lakeman AD, Nahmias AJ, Whitley RJ. Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis. 1986;13:61-66.
16. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections. Ann Intern Med. 1983;98:958-972.
17. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116:197-202.
18. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes. J Infect Dis. 1993;167:942-946.
19. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol. 1992;179:137-158.
20. Dix RD, Pereira L, Baringer JR. Use of monodonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun. 1981;34:192-199.
21. Balachandran N, Bacchetti S, Rawls WE. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun. 1982;37:1132-1137.
22. Byars NE, Fraser-Smith EB, Pecyk RA, et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine. 1994;12:200-209.
23. Wachsman M, Aurelian L, Smith CC, Lipinskas BR, Perkus ME, Paoletti E. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J Infect Dis. 1987;155:1188-1197.
24. Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2. Ann Intern Med. 1995;122:889-898.
25. Ashley R, Cent A, Maggs V, Nahmias A, Corey L. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med. 1991;115:520-526.
26. Safrin S, Arvin A, Mills J, Ashley R. Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. J Clin Microbiol. 1992;30:1312-1314.
27. Ashley R. Herpes simplex virus. In: Lenette E, ed. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. 7th ed. Washington, DC: American Public Health Association; 1995:375-395.
28. Dalessio J, Ashley R. Highly sensitive enhanced chemiluminescence immunodetection method for herpes simplex virus type 2 Western immunoblot. J Clin Microbiol. 1992;30:1005-1007.
29. 2 and gD as antigens for type-specific serologic assay to diagnose prior infection with HSV-1 or HSV-2. Abstract presented at: Eurogin International Conference on Herpes Viruses and Genital Pathology; Paris, France; October 24, 1996.
30. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis. 1990;161: 653-660.
31. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, non-compliance, and stratification. Biometrics. 1986;42: 507-519.
32. Bernstein D, Lagakos S. Sample size and power determination of stratified clinical trials. J Stat Comp Sim. 1978;8:65-73.
33. Fleiss JL. The Design and Analysis of Clinical Experiments. New York, NY: John Wiley & Sons; 1986.
34. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill; 1971.
35. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187-220.
36. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York, NY: John Wiley & Sons; 1991.
37. Kleinbaum DC, Kapper LL, Muller KE. Applied Regression Analysis and Other Multi variable Methods. Boston, Mass: PWS-Kent Publishing Co; 1988.
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 457-481.
39. SAS Institute Inc. SAS User's Guide: Statistics, Version 6. 2nd ed. Cary, NC: SAS Institute; 1985.
40. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. J Clin Invest. 1997; 99:1092-1097.
41. Terhune SS, Coleman KT, Sekulovich R, Burke RL, Spear PG. Limited variability of glycoprotein gene secuences and neutralizing targets in herpes simplex virus type 2 isolates and stability on passage in cell culture. J Infect Dis. 1998;178:8-15.
42. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med. 1987; 316:240-244.
43. Rooney JF, Felser JM, Ostrove JM, Straus SE. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med. 1986;314:1561-1564.
44. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis. 1985; 12:33-39.
45. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333: 770-775.